PolyPEPI 1018
Alternative Names: PolyPEPI™ 1018; PolyPEPI™ 1018 CRC VaccineLatest Information Update: 28 Feb 2025
At a glance
- Originator Treos Bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Adjunctive treatment, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (SC, Injection)
- 03 Jun 2024 Efficacy, adverse events and immunogenicity data from a phase III OBERTO-301 trial in Colorectal cancer released by Treos Bio
- 31 May 2024 Efficacy, adverse events and immunogenicity data from a phase III OBERTO-301 trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)